### Table 1 Summaries for the partially blind signature schemes

2003

### Table 1. Cost of the signature generation phase in the blind threshold signature scheme and that in the underlying blind signature scheme.

"... In PAGE 14: ... We will use as a measure the number of modular exponentiations and that of modular inverses required by a single player during execution of our signature generation protocol. Table1 shows a comparison between the blind threshold signature scheme and its underlying blind signature scheme. In this table, Scheme 1 denotes the blind threshold signature scheme described in Section 4, and Scheme 1* denotes its corresponding underlying blind signature scheme.... ..."

### Table 1: Cost of the signature generation in the blind threshold signature scheme and that in the underlying blind signature scheme. The requester

2002

"... In PAGE 18: ... which contains + 1 modular multiplications and ? 1 modular additions. Table1 il- lustrates the comparison of the blind threshold signature scheme and its underlying blind signature scheme. In this table, Scheme 1 denotes the blind threshold signature scheme and Scheme 1 denotes its corresponding underlying blind signature scheme.... ..."

Cited by 3

### Table 1: Cost of the signature generation phase in the blind threshold signature scheme and that in the underlying blind signature scheme. The requester

"... In PAGE 7: ... We use as a measure the number of modular exponentiations and that of modular inverses required by a sin- gle player during the execution of our signature generation protocol. Table1 illustrates the com- parison of blind threshold signature scheme and its underlying blind signature scheme. In this ta- ble, Scheme 1 denotes the blind threshold signa- ture scheme in Section 4 and Scheme 1 denotes its corresponding underlying blind signature scheme.... ..."

### Table 4: Message Sizes for Blind Signatures

"... In PAGE 5: ...able 3: Summary of Environmental Constraints ......................................................................... 25 Table4 : Message Sizes for Blind Signatures .... In PAGE 63: ... In particular, it requires a periodic interactive exchange between OBUs and the CA. This exchange consists of two round trips with sizes shown in Table4 below. ... ..."

### Table 1: Cost of the signature generation phase in the fair blind threshold signature scheme and that in the underlying fair blind signature scheme. The requester

1997

"... In PAGE 17: ...ignature scheme in Section 3.3.1 and Scheme 1 denote the corresponding underlying blind signature scheme. Table1 illustrates the comparison of the fair blind threshold signature scheme and the underlying fair blind signature scheme. Comparative to the underlying... ..."

Cited by 1

### Table 1: Comparison of present work to previous blind signatures

2005

"... In PAGE 4: ... Note that the resulting signature from the signing protocol is about half the size of an RSA based Chaum blind signature. Table1 compares the round complexity of our construction in comparison to previous blind signature schemes. The construction is proven to satisfy the two properties of [JLO97] model as follows: the blindness property is ensured under the Decisional Composite Residuosity assumption of [Pai99] and the Decision Linear Diffie-Hellman assumption of [BBS04].... ..."

Cited by 3

### Table 2 Partial STEP file of through and blind holes

"... In PAGE 4: ... LINE A line in which the geometry is defined by the associated surface, boundary and vertices. An example of STEP file for a blind/through hole is shown in Table2 . In general, the geometrical data of a blind/through hole is as follows: (1) The entity #27, refers to CIRCLE with the radius of 2.... ..."

### Table 2. Response of Target Tumors* During the Blinded Phase

"... In PAGE 3: ... These were intensively pretreated patients with long- standing disease who had few, if any, treatment options. RESPONSE OF TARGET TUMORS As shown in Table2 , the response rate for the target tu- mor (CR+PR sustained H1135028 days) was 29% (35/119) for patients in the cisplatin/epinephrine gel group and 2% (1/ 59) for patients in the placebo gel group, a statistically sig- nificant difference (PH11021.001).... ..."